Navigation Links
Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
Date:12/3/2008

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today announced that data related to the Company's series of novel compounds that inhibit spleen tyrosine kinase (Syk) and its novel universal Factor Xa inhibitor antidote will be presented at the annual meeting of the American Society of Hematology (ASH) at the Moscone Center in San Francisco during December 6-9, 2008.

Portola's Syk inhibitor program is focused on developing specific oral inhibitors of this key signaling pathway, which modulate inflammation, certain cancers and thrombosis. The Company plans to study its compounds initially in rheumatoid arthritis and non-Hodgkin's Lymphoma and eventually intends to explore their potential in other inflammatory diseases and cancers. Portola is developing its universal Factor Xa inhibitor antidote to neutralize the effect of small molecule Factor Xa inhibitors in patients experiencing major bleeding and for patients undergoing emergent or elective surgery.

Details of the ASH presentations are below and full abstracts can be viewed on the ASH website at http://www.hematology.org.

Syk Inhibitor Program

"Specific Inhibition of Syk is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin's Lymphoma Cell Lines without Concomitant Inhibition of JAK" (abstract # 1794)

Saturday, December 6, 5:30 PM

Hall A (Moscone Center)

"PRT060318, a Novel Syk Inhibitor, Prevents Heparin-Induced Thrombocytopenia in a Transgenic Mouse Model" (abstract # 269)

Monday, December 8, 7:00 AM

3007-3009-3011 - West (Moscone Center)

"Specific Pharmacological Targeting of the Syk Kinase Activity in Platelets: A Nove
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
2. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
3. Novel Technology Breaks Through Cancer Pain
4. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
5. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
6. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
7. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
8. NIST team develops novel method for nanostructured polymer thin films
9. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
10. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
11. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. ... on providing advanced testing solutions for the detection of ... will present at the Sidoti & Company Emerging Growth ... will be held at the New York Marriott Marquis. ... will be available through the investor relations section of ...
(Date:8/26/2015)... FRANCISCO , Aug. 26, 2015  Platform ... that it has received a $1.5M Phase II ... (NIH) to further develop its therapeutic agent to ... clinical need in end stage renal disease (ESRD) ... the National Institute of Diabetes and Digestive and ...
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a ... business relationships with local sponsors in southern California. The Clinical Trial Management Expert CRO ... processes and regulatory pathways., , Stem Cell Meeting on ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Nets to Prevent Serious Health Hazards ... Associated with Diethylene ... Pharmacopeial (USP),Convention today announced a revised Glycerin monograph in ... United States. The,revision strengthens safety nets to prevent serious ...
... The following was issued,today by the Greater Baltimore ... CEO, Greater Baltimore Committee, 140 company owners, executives ... The third annual Greater Baltimore Region Bioscience Awards, ... / Breakfast & Registration, 8:45 - 9:30 a.m. ...
... March 17 Mercury Therapeutics,Inc. (MTI), a ... protein,kinase targeted drugs, announces that it has ... advise on its strategic and partnering,opportunities, with ... shareholders., This appointment follows a significant ...
Cached Biology Technology:USP Announces Revised Glycerin Monograph 2USP Announces Revised Glycerin Monograph 3Greater Baltimore Committee to Announce Winners of Third Baltimore Region Bioscience Awards at Ceremonies on March 18 2Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities 2Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities 3
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/6/2015)... SAN JOSE, Calif. , Aug. 6, 2015 ... the leading developer of human interface solutions, today ... and TouchPad technologies on Windows 10. Microsoft leveraged ... fundamental to the operating system. ... and drivers are fully certified with Microsoft,s Precision ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... A drug being tested to treat cancer could also ... at the University of Edinburgh found that the drug ... exacerbate symptoms associated with asthma. The findings could lead ... are resistant to steroids, which are commonly used in asthma ...
... cancer mortality in children. Even if a cure is ... treatment which can be harmful to the developing brain. ... treatment methods. The most important childhood brain tumors are ... patients each year in Germany, and pylocytic astrocytoma, which ...
... German and Portuguese . So Paulo/ ... impact on climate change than has previously been thought. The combined ... after habitat fragmentation can be up to 40 per cent less ... This is the conclusion reached by German and Brazilian researchers who ...
Cached Biology News:Germany starts its part in the International Cancer Genome Project 2Germany starts its part in the International Cancer Genome Project 3Germany starts its part in the International Cancer Genome Project 4Tropical forests affected by habitat fragmentation store less biomass and carbon dioxide 2Tropical forests affected by habitat fragmentation store less biomass and carbon dioxide 3
... for interferons are cytopathic effect inhibition assays, also ... types include; tissue culture supernatents; serum from PK ... one unit is defined as the quantity of ... effect of viral infection by 50%. ...
Request Info...
...
... is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Biology Products: